14.9% Average Loss With Semaglutide at 68 Weeks
The STEP 1 trial is a foundational peer-reviewed study of once-weekly semaglutide 2.4 mg with lifestyle intervention. Its result describes an average trial outcome under a specific eligibility, dosing, and follow-up protocol—not a promise of a particular outcome from an online program.
Mean body-weight change was −14.9% with semaglutide and −2.4% with placebo.
More participants receiving semaglutide reached 5%, 10%, and 15% weight-reduction thresholds than those receiving placebo. Nausea and diarrhea were the most common adverse events; they were generally transient and mild to moderate, and more semaglutide participants discontinued because of gastrointestinal events.
Turn the study result into a better program comparison
Ready to compare GLP-1 programs? Use the review details to separate the questions a trial does not settle: monthly price terms, brand-name versus compounded product status, clinical follow-up, and each provider’s checkout requirements. The programs below have category-matched GLP-1 offers and are not study-endorsed.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 1,961 adults with obesity or overweight plus a weight-related condition, without diabetes
- Follow-up
- 68 weeks
- Treatment comparison
- Once-weekly subcutaneous semaglutide 2.4 mg compared with placebo, alongside lifestyle intervention
- Study design
- Double-blind, randomized, placebo-controlled trial
A study result is not a personal treatment plan
Semaglutide availability, prescription appropriateness, insurance terms, and dose progression must be evaluated by a licensed clinician. A provider’s online intake process cannot predict whether an individual will be prescribed a particular medication or achieve the study-average result.
Compare semaglutide and tirzepatide programsWhat this result does not show
- The trial studied once-weekly semaglutide 2.4 mg with lifestyle intervention, not every semaglutide formulation or care model.
- Participants did not have diabetes and met specific BMI and clinical eligibility criteria.
- Average results do not determine an individual’s eligibility, coverage, medication access, side-effect profile, or outcome.
- The study was funded by Novo Nordisk; the paper, protocol, and disclosures are linked at the end of this article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at New England Journal of Medicine